Pancreatic mucinous cystic tumor in Turner syndrome: How a tumor bends to a genetic disease

Marco Pizzi a, Gianmaria Pennelli a, Isabella Merante-Boschin b, Matteo Fassan a, Maria Rosa Pelizzo b, Massimo Rugge a,⁎

a Department of Medicine DIMED, Surgical Pathology & Cytopathology Unit, University of Padova, Italy
b Surgery Unit, Department of Surgical Oncology and Gastroenterology Sciences, University of Padova, Italy

A R T I C L E   I N F O

Article history:
Received 28 January 2013
Received in revised form 9 September 2013
Accepted 9 September 2013
Available online 12 September 2013

Keywords:
Pancreatic mucinous cystic neoplasm
Cystadenoma
Cystadenocarcinoma
Turner syndrome

A B S T R A C T

INTRODUCTION: Mucinous cystic neoplasms (MCN) are uncommon tumors of the pancreatic corpus/tail occurring mostly in middle-aged women, with a variable clinico-biological behavior. On histology, MCNs concurrently show an epithelial mucosecreting component with ovarian-type stromal cells.

PRESENTATION OF CASE: This report describes the first case of a pancreatic MCN with no ovarian-type stroma in a patient with Turner syndrome (TS).

DISCUSSION: The mesenchymal component of MCN presumably results from the intra-pancreatic entrapment of ovarian stroma during embryogenesis. In our case, the absence of such stromal component may relate to the “dyssygenetic” changes in the ovary involved in TS.

CONCLUSION: The present case of primary pancreatic MCN arising in a TS-patient triggers some original speculation on the morphogenesis of pancreatic MCN, also expanding the current clinico-pathological knowledge of this extremely rare entity.

© 2013 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. All rights reserved.

1. Introduction

Pancreatic cystic neoplasms include both benign and malignant diseases. Within otherwise solid pancreatic tumors, cystic changes may result from necrosis/hemorrhage due to the neoplasm’s growth (i.e. degenerative cysts). Among “natively” cystic tumors, the neoplastic cells’ phenotype distinguishes serous from mucinous subtypes. Based on its epidemiological, clinical and pathological profile, the mucinous subgroup is further divided into mucinous cystic neoplasms (MCN) and intraductal papillary mucinous neoplasms (IPMN). A distinctive histological feature of MCN is the coexistence of an epithelial mucosecreting component with ovarian-type stroma (which is lacking in IPMN).

Turner syndrome (TS) belongs to the spectrum of the “premature ovarian failures”, and is characterized by early ovarian demise with insufficient circulating levels of female sex steroids.

This report describes the first case of a primary pancreatic MCN with no ovarian stroma, occurring in a TS patient.

2. Case report

In September 2011, a 42-year-old Caucasian woman with TS was referred to the Surgery Department of Padua Teaching Hospital (Padua, Italy) with a cystic lesion (11 cm in size) of the tail of the pancreas. The lesion had initially been identified when the patient was 18 years old (an incidental ultrasound [US] finding), when it had been diagnosed as an “adrenal cyst”. At the time of this initial assessment, the lesion had been 4.5 cm in size and featured a well-defined, thin wall and a homogenous fluid content. Laboratory tests (including serum tumor markers) had revealed nothing of significance. Subsequent annual US follow-up showed a gradual enlargement of the cyst, with newly appearing mural nodules, and changes in the cyst’s contents (from fluid to hemorrhagic/corpusculated). In 2007, a check-up revealed above-normal CA19-9 levels (901.6 U/mL [normal range: 0–37 U/mL]), and subsequent abdominal computed tomography definitively located the lesion within the pancreatic tail (Fig. 1). Neither endoscopic US, nor cytology of the cystic fluid were performed. The patient refused surgery until 2011, when a pancreatic tail resection with splenectomy was performed.

The gross surgical specimen featured a single, rounded cyst with a fibrous (locally calcified) pseudo-capsule. The cut surface disclosed a multi-locular cyst filled with hemorrhagic mucus; solid mural nodules coexisted with intra-luminal protrusions (Fig. 2A).
On histology, both the cystic wall and the small papillary projections were lined by columnar epithelia with basally located nuclei and clear cytoplasm; foci of mild architectural/cytological atypia (i.e. low-grade dysplasia) were also found (Fig. 2B). The large papillary fronds featured foci of high-grade dysplasia, where irregular papillae were lined by multiple layers of cubic/columnar epithelia with atypical/irregular nuclei, and prominent nucleoli (Fig. 2C). Micro-glandular nests (consistent with early stromal cancer invasion) were also visible at the implant of the papillary structures. The sub-epithelial fibrous stroma was consistently hypocellular, with no evidence of ovarian commitment (Fig. 2D). Moderate- to high-grade inflammatory infiltrate was associated with micro-invasive carcinoma.

Epithelial cells consistently expressed CK7, CK19, CK8/18, monoclonal CEA, and EMA. Nuclear staining for CDX2 and apical membrane staining for CD10 were also found, with a focal (but sharp) positivity for CK20 (Fig. 2E-G). Chromogranin, synaptophysin and nuclear β-catenin stains were negative. Both high-grade dysplasia and micro-invasive cancer cells showed consistent immunostaining for both p53, and Ki67. Fibrous (vimentin-positive) stroma featured no staining for either estrogen or progesterone receptors, and for smooth muscle actin antigen (Fig. 2D) (Table 1).

A diagnosis of mucinous cystic micro-invasive carcinoma of the pancreas (adjacent to low- and high-grade dysplasia) was finally established (pT2 N0 M0, stage IB; complete resection with negative histological margins [R0]). The patient recovered rapidly after surgery and is currently (January 2013) alive, with no evidence of disease on imaging.

3. Discussion

Turner syndrome (TS) is caused by the partial or complete lack of a sex chromosome, which occurs in about 40–50 per 100,000 live-born girls. The spectrum of the syndrome basically results from gene haplo-insufficiency on the X chromosome, which also leads to insufficient circulating levels of female sex steroids and premature ovarian failure, associated with ovarian stroma fibrosis and oocyte degeneration.3,4

Pancreatic MCN is a cyst-forming tumor in which mucin-producing neoplastic epithelia coexist with ovarian-type stroma.1 The coexistence of these two neoplastic components (epithelial-mucinous and non-epithelial ovarian-type) is the histological hallmark of MCN and differentiates such tumors from IPMN.1,2 although the ovarian-type stroma is variably represented3 and may be hypocellular/fibrotic in some cases (mainly in large MCN).1

In the present case, despite the lack of ovarian-type stroma, several clinicopathological features firmly support a diagnosis of MCN rather than IPMN: (i) the tumor occurred in the pancreatic tail of a young (18-year-old) female; (ii) it consisted of a single multi-locular cyst (with a calcified pseudo-capsule); (iii) none of the serial histology sections obtained from the surgical specimens featured any communication between the cyst and the pancreatic duct tree; (iv) the neoplastic cells consistently expressed CDX2, CK20 and CD10 antigens. IPMNs, on the other hand, mainly affect elderly males, they are usually located in the pancreatic head and involve the main branches of the pancreatic ducts,6,7 and they do not usually reveal staining for CDX2, CK20 and CD10,8,9.

The occurrence of a cystic pancreatic tumor in a young female patient also suggests the differential diagnosis with a solid-pseudopapillary neoplasm of the pancreas (SPNP). The diagnosis of MCN, however, was supported by: (i) absence of solid areas consisting of poorly cohesive monomorphic cells, admixed with hyalinized/myxoid stromal bands; (ii) negative nuclear immunostain for β-catenin10; (iii) the absence of “regressive” features (i.e. cholesterol crystals) coexisting with foreign-body giant cells.

Table 1
Immunohistochemical profiling of the neoplasm.

| Component       | Clone | Working Dilution | Manufacturer | Immunostaining score |
|-----------------|-------|------------------|--------------|----------------------|
| Epithelial      | CK7   | OV T12/30        | Cell-Marque, USA | 3+                   |
|                 | CK8/18| 503              | Thermo Scientific, UK | 3+                   |
|                 | CK19  | RCIT 108         | Bio Genex, NL | 3+                   |
|                 | CK20  | ITS208           | Cell-Marque, USA | 1+                   |
| Monoclonal CEA  | CE31  | 1:400            | Roche, France | 2+                   |
| EMA             | E29   | 1:200            | Thermo Scientific, UK | 3+                   |
| CD10            | 56C6  | 1:20             | Dako, Denmark | 3+                   |
| CDX2            | EPR2764y | 1:100           | Dako, Denmark | 2+                   |
| p53             | D07   | 1:100            | Cell-Marque, USA | 3+                   |
| Chromogranin A  | DAK-A3| 1:100            | Dako, Denmark | 0                    |
| Synaptophysin   | SY38  | 1:200            | Dako, Denmark | 0                    |
| Stromal component | ER   | 6F11             | Leica, UK | 0                    |
|                 | PR    | LPGCR312         | Leica, UK | 0                    |
| Smooth muscle actin (SMA) | 1A4 | 1:100            | Cell-Marque, USA | 0                   |
| Vimentin        | V9    | 1:200            | Cell-Marque, USA | 3+                   |

* O: no expression; 1+: <30% of the cells; 2+: 30–60% of the cells; 3+: >60% of the cells.
Fig. 2. Histological and immunohistochemical features. (A) At low magnification, irregular branching papillae project into the cystic lumen. Periodic acid-Schiff stain (PAS), original magnification 5×. (B and C) At higher magnification, the cyst is lined with columnar/cubic epithelia with basally placed nuclei and pale cytoplasm. Cytological atypia ranges from low (B) to high grade (C). The implant of the neoplastic lesion shows microglandular structures consistent with stromal micro-invasion (micro-invasive carcinoma) (C). H&E, original magnification 40×. (D) On both morphology and immunohistochemistry, the stoma consistently lacks ovarian-type features (no estrogen receptor immunostaining was documented). (E–G) Epithelial cells stain positive for both cytokeratin 19 (CK19) (E), CK20 (F) and CDX2 (G), supporting the diagnosis of MCN rather than IPMN.
As for the cancer’s morphogenesis, we might speculate that the lack of ovarian-type stroma was part of the “gonadal failure” typical of TS. Judging from its histological features and immunohistochemical profiling, the mesenchymal component of MCN presumably results from the intra-pancreatic entrapment of ovarian stroma in early embryogenesis. This morphogenetic hypothesis is plausibly supported by: (i) the possible occurrence of neoplastic stroma luteinization; (ii) the stromal expression of sex-cord antigens; and (iii) the elective location of MCNs within the pancreatic body/tail (proximal to the left primordial gonads).1,11

This unique case of pancreatic MCN arising in a TS-patient raises the question on the biological relationship between the native ovarian stroma and the “ovarian-type stroma” of the pancreatic MCNs. In the present case, the consistent involvement (i.e. involution) of the ovary stroma in both its native-ovarian and neoplastic-pancreatic locations would support the hypothesis of pancreatic MCNs as originating from pancreatic heterotopy of ovarian tissue. On this respect, some additional information could be potentially achieved by comparing the phenotypes of the pancreatic with the ovarian MCNs. Ovarian MCNs arising in Turner syndrome, however, have been only anecdotally reported and, in all these reports, the morphology of the non-epithelial neoplastic component has been only shortly detailed.11–15

In conclusion, the present case of primary pancreatic MCN arising in a TS-patient triggers some original speculation on the morphogenesis of pancreatic MCN, also expanding the current clinico-pathological knowledge of this extremely rare entity.

Conflict of interest statement
None declared.

Funding
None declared.

Consent
Written informed consent has been obtained and unnecessary identifying details have been omitted. The patient gave her written informed consent. The institute's ethical rules were followed.

Author contributions
Marco Pizzi: study design and writing. Gianmaria Pennelli: histological examination and study design. Matteo Fassan: study design and data collection. Isabella Merante-Boschini: clinical and serological data collection. Maria Rosa Pelizzo: clinical and serological data collection. Massimo Rugge: study design and writing.

References
1. Zamponi G, Fukushima N, Hruban RH, Klöppel G. Mucinous cystic neoplasm of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer (IARC); 2010.
2. Zamponi G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, et al. Cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999;23(4):410–22.
3. Sybert VP, Mc Cauley E. Turner’s syndrome. N Engl J Med 2004;351(12):1227–38.
4. Elsheikh M, Dunger DB, Conway GS. Turner’s syndrome in adulthood. Endocr Rev 2002;23(1):120–40.
5. Lee WA. Mucinous cystadenoma of the pancreas with predominant stroma creating a solid tumor. World J Surg Oncol 2002;3:59.
6. Crippa S, Fernández-Del Castillo C, Salvia R, Finkelstein D, Bassi C, Domínguez I, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 2010;8(2):213–9.
7. Hruban RH, Pitman MB, Klimstra DS. Mucinous cystic neoplasm. In: Hruban RH, Pitman MB, Klimstra DS, editors. Tumors of the pancreas. Washington: Armed Force Institute of Pathology; 2007.
8. Handra-Luca A, Fléjou JF, Rulaf P, Corsos O, Belghiti J, Buzniewski P, et al. Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology 2006;48(7):813–21.
9. Nishigami T, Onodera M, Torii I, Sato A, Tao IH, Kushima K, et al. Comparison between mucinous cystic neoplasm and intraductal papillary mucinous neoplasm of the branch duct type of the pancreas with respect to expression of CD10 and cytokertatin 20. Pancreas 2009;38(5):558–64.
10. Klöppel G, Hruban RH, Klimstra DS, Maitra A, Morohoshi T, Notohara K, et al. Solid-pseudopapillary neoplasm of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer (IARC); 2010.
11. Erdogan D, Lamers WH, Offerhaus GJ, Busch OR, Gouma DJ, van Gulik TM, et al. Cystadenomas with ovarian stroma in liver and pancreas: an evolving concept. Dig Surg 2006;23(3):186–91.
12. Sait KH, Alkhattabi MA, Alkushi AO, Alqahtani MH. Ovarian mucinous cystadenoma in a female with Turner syndrome. Saudi Med J 2004;25(9):1270–3.
13. van der Bijl AE, Fleuren GJ, Kentier GG, de Jong D. Unique combination of an ovarian gonadoblastoma, dysgerminoma, and mucinous cystadenoma in a patient with Turner’s syndrome: a cytogenetic and molecular analysis. Int J Gynecol Pathol 1994;13(3):267–72.
14. Murphy GF, Welch WR, Urcuyo R. Brenner tumor and mucinous cystadenoma of borderline malignancy in a patient with Turner’s syndrome. Obstet Gynecol 1979;54(5):660–3.
15. Goldberg MB, Scully AL. Gonadal malignancy in gonadal dysgenesis: papillary pseudomucinous cystadenocarcinoma in a patient with Turner’s syndrome. J Clin Endocrinol Metab 1967;27(3):341–7.